



Virus Neutralizing and Enhancing Antibodies

Guest Editor:

Dr. Surender Khurana

Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD 20993, USA

Deadline for manuscript submissions:

closed (30 June 2022)

Message from the Guest Editor

Dear Colleagues,

This Special Issue of *Vaccines* aims at addressing the unresolved key issues that hamper our understanding of the interactions between viruses and antibodies. The new presented studies will shed light on the multifaceted biological role that antibodies play during the course of virus infections. Both original research and review articles are welcome. Potential topics include, but are not limited to:

- Antigenic evolution and immunity to virus;
- Antibody and human cellular immune cell responses;
- Broadly cross-reactive and universal immunity to virus;
- Antigens and antibody in pathogenesis of viral infections;
- Dynamics of the antibody response during viral infections.
- We look forward to receiving your interested contribution.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)